Insulet
Open
$147.78
Prev. Close
$147.67
High
$147.97
Low
$147.52
Market Snapshot
$10.4B
34.3
5.98
$2.07B
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts and currently employs 5,400 full-time employees. The company went IPO on 2007-05-15. The company is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. The company also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts and currently employs 5,400 full-time employees. The company went IPO on 2007-05-15. The company is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. The company also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
Recently from Cashu
Insulet Unveils Omnipod 6 for Enhanced Diabetes Management and Automation
Insulet Corporation (Ticker: PODD) has recently made significant strides in diabetes management with the introduction of its investigational device, the Omnipod 6, showcased at the American Diabetes A…
Insulet Reports Positive Clinical Data for Omnipod 6 and Automated Diabetes Management Solutions
Insulet Corporation (Ticker: PODD) announces promising clinical data for its Omnipod 6 and fully closed loop systems, which demonstrate significant improvements in glucose control for patients living…
Insulet Advances Diabetes Care with Innovative Omnipod System and Strategic Partnerships
Insulet Corporation (Ticker: PODD) is making strides in the diabetes care market with its innovative products, primarily the Omnipod insulin management system. Omnipod: A Technological Breakthrough in…
Insulet Faces Major Recall Challenges Amid Safety Concerns Over Omnipod Insulin Delivery System
Insulet (Ticker: PODD) navigates significant challenges following a recent voluntary recall of its Omnipod insulin delivery system. The recall impacts approximately 7 million insulin Pods worldwide an…